News

Published on 9 Feb 2023 on Simply Wall St. via Yahoo Finance

With 35% stake, Vera Therapeutics, Inc. (NASDAQ:VERA) seems to have captured institutional...


Article preview image

Every investor in Vera Therapeutics, Inc. (NASDAQ:VERA) should be aware of the most powerful shareholder groups. We can see that institutions own the lion's share in the company with 35% ownership. That is, the group stands to benefit the most if the stock rises (or lose the most if there is a downturn).

Since institutional have access to huge amounts of capital, their market moves tend to receive a lot of scrutiny by retail or individual investors. As a result, a sizeable amount of institutional money invested in a firm is generally viewed as a positive attribute.

Let's delve deeper into each type of owner of Vera Therapeutics, beginning with the chart below.

NASDAQ.VERA price evolution

Want to become a better investor?

Start tracking your investments with Statfolio

Sign up for free
Related News
Vera Therapeutics, Inc.'s (NASDAQ:VERA) high institutional ownership speaks for itself as stock...

Key Insights Significantly high institutional ownership implies Vera Therapeutics' stock price is...

Simply Wall St. via Yahoo Finance 6 May 2024

Insider Sells at Vera Therapeutics Inc: SVP, Finance, Chief Accounting Officer Joseph Young ...

Vera Therapeutics Inc (NASDAQ:VERA), a clinical-stage biotechnology company focused on developing...

GuruFocus.com via Yahoo Finance 12 Apr 2024

Vera Therapeutics executive sells over $228k in company stock

In a recent transaction, Joseph R. Young, the Senior Vice President of Finance and Chief Accounti...

Investing.com 11 Apr 2024

Vertex's Alpine Acquisition: Unpacking Analyst Predictions on Povetacicept's Potential Impact -...

On Wednesday, Vertex Pharmaceuticals Incorporated VRTX agreed to acquire Alpine Immune Sciences I...

Benzinga 11 Apr 2024

Vertex Pharma’s takeover of Alpine Immune is a strategic fit: analysts

Alpine Immune’s lead candidate is being evaluated as a potential treatment for IgA Nephropathy, o...

Market Watch 11 Apr 2024

Vertex to Pay $4.9 Billion for Kidney Disease Drug Developer

(Bloomberg) -- Vertex Pharmaceuticals Inc. agreed to buy Alpine Immune Sciences Inc. for a total ...

Bloomberg via Yahoo Finance 11 Apr 2024

Estimating The Fair Value Of Vera Therapeutics, Inc. (NASDAQ:VERA)

Key Insights Using the 2 Stage Free Cash Flow to Equity, Vera Therapeutics fair value estimate is...

Simply Wall St. via Yahoo Finance 11 Feb 2024

FMR LLC Adjusts Stake in Vera Therapeutics Inc

Recent Transaction Overview On October 31, 2023, investment firm FMR LLC (Trades, Portfolio) made...

GuruFocus.com via Yahoo Finance 14 Nov 2023

Wall Street Analysts Believe Vera Therapeutics, Inc. (VERA) Could Rally 86.76%: Here's is How to...

Vera Therapeutics, Inc. (VERA) closed the last trading session at $12.76, gaining 23.4% over the ...

Zacks via Yahoo Finance 14 Nov 2023

Down -34.74% in 4 Weeks, Here's Why You Should You Buy the Dip in Vera Therapeutics, Inc. (VERA)

Vera Therapeutics, Inc. (VERA) has been on a downward spiral lately with significant selling pres...

Zacks via Yahoo Finance 18 Oct 2023